$29.00—Stale · unknown old
XETRA • Last print unknown ago
$29.00—Stale · unknown old
PharmaSGP Holding SE specializes in the development and marketing of generic pharmaceuticals, primarily focusing on the German and European markets. Its competitive position is bolstered by a high gross margin of 90.9% and a strong return on equity of 29.8%, driven by a portfolio of over 150 products across various therapeutic areas.
PharmaSGP generates revenue through the sale of generic drugs, leveraging its high gross margins and low debt levels to maintain pricing power. The company's competitive advantage lies in its established relationships with pharmacies and healthcare providers, as well as its ability to quickly adapt to market demands.
Regulatory approvals for new generic products
Changes in pricing regulations in Germany and the EU
Market share gains in the generic drug segment
Competitive pricing strategies against branded drugs
Regulatory changes affecting drug pricing and market access
Technological advancements in drug development that could outpace generic offerings
Increased competition from other generic manufacturers
Potential entry of new players into the generic drug market
Low liquidity risk due to a current ratio of 2.68
Limited financial flexibility due to minimal debt
moderate - As a healthcare provider, PharmaSGP's demand is somewhat insulated from economic downturns, but overall spending on pharmaceuticals can be affected by GDP growth.
Minimal impact as the company has low debt levels; however, rising rates could affect consumer spending on healthcare products.
minimal - The company's low debt-to-equity ratio indicates limited reliance on credit markets.
growth - Investors are likely attracted to the company's strong revenue and net income growth rates.
low - The company has demonstrated stable performance with a low beta.